TYK2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08928(TYK2 Antibody) at dilution 1/130. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08928(TYK2 Antibody) at dilution 1/130. (Original magnification: ×200)    

  
  

Tyrosine kinase 2 (TYK2), a member of the Janus kinase (JAK) family, plays a critical role in mediating cytokine signaling pathways involved in immune regulation and inflammation. It is activated by cytokines such as interleukin (IL)-12. IL-23. and type I interferons, which are implicated in autoimmune and inflammatory diseases like psoriasis, lupus, and inflammatory bowel disease. Traditional small-molecule TYK2 inhibitors often target the kinase domain, but selectivity challenges may lead to off-target effects. TYK2 antibodies, however, offer a more targeted approach by specifically blocking extracellular interactions or modulating intracellular signaling.

Recent advancements focus on developing monoclonal antibodies (mAbs) that either neutralize TYK2 itself or interfere with its association with cytokine receptors. For instance, some antibodies bind to the TYK2 pseudokinase domain (JH2), stabilizing its autoinhibitory conformation and preventing downstream STAT activation. This allosteric inhibition reduces pro-inflammatory signaling while potentially preserving homeostatic functions of other JAK family members.

TYK2 antibodies are gaining attention as potential therapeutics due to their high specificity and reduced systemic toxicity compared to broad JAK inhibitors. Several candidates are in preclinical or early clinical trials, particularly for autoimmune conditions. Challenges remain, including optimizing delivery, minimizing immunogenicity, and ensuring long-term safety. Ongoing research also explores bispecific antibodies or engineered formats (e.g., nanobodies) to enhance efficacy. If successful, TYK2 antibodies could complement or surpass existing biologics in managing complex immune disorders.